Aromatherapy as Treatment for Nausea and Vomiting of Pregnancy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pregnancy Emesis
- Sponsor
- Albany Medical College
- Enrollment
- 17
- Locations
- 1
- Primary Endpoint
- Mean difference in Pregnancy-Unique Quantification of Emesis (PUQE) score
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
A double-blinded randomized controlled trial comparing essential oil aromatherapy versus placebo for treatment of first trimester nausea and vomiting of pregnancy.
Detailed Description
This is a double-blinded randomized controlled trial investigating the utility of essential oils for aromatherapy, compared to placebo, for treatment of nausea and vomiting in the first trimester of pregnancy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pregnancy at \<14 weeks gestation
- •English-speaking
- •Baseline PUQE score \>=6
Exclusion Criteria
- •Non-compliant with prenatal care or study procedures
- •Hyperemesis gravidarum
- •Allergies to perfumes, essential oils or cosmetics
- •Abnormal sense of smell
- •Known acute or chronic GI disease
- •Use of prescription anti-emetics
Outcomes
Primary Outcomes
Mean difference in Pregnancy-Unique Quantification of Emesis (PUQE) score
Time Frame: First trimester of pregnancy
PUQE score is a validated measure of nausea and vomiting in pregnancy. It is a reliable tool used to measure the severity of nausea and vomiting of pregnancy. It is a questionnaire that measures the number of times in 24 hours a patient wretches, vomits, or feels nauseous. The minimum score is 3, and the maximum is 15. Participants will have PUQE scores calculated at baseline (during enrollment in the first trimester of pregnancy, at whatever age they are at), and after one month of aromatherapy use with either essential oils or placebo, with the mean difference from baseline compared as primary outcome. The Time Frame for participation will be from enrollment until the end of the first trimester (13th week of pregnancy), which, depending on gestational age in weeks at enrollment, may be up to 8 weeks.